Cadre price to free cash flow CDRE
Market value divided by free cash flow over the last twelve months, since 2022.
- Today, Nov 2, 2026
- 17.3×
- 4-year median
- 24.6×
- Against its 4-year history
- 7th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 13.5× to 57.0×
- Peer median
- 20.9×
Cadre's price to free cash flow is 17.3× as of Nov 2, 2026.
That is below its 4-year median of 24.6×, lower than on 93% of days in the last 4 years.
Over that time it ranged from 13.5× in Oct 2026 to 57.0× in Jan 2025.
The median for 10 medical instruments and supplies stocks of a similar size is 20.9×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 17.3× | 13.5× | 29.4× |
| 2025 | 27.8× | 26.7× | 57.0× |
| 2024 | 46.2× | 18.6× | 51.2× |
| 2023 | 21.6× | 16.4× | 25.3× |
| 2022 | 21.4× | 21.4× | 34.3× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Cadre's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| CDRECadre | 17.3× |
| EYENational Vision | 27.6× |
| STAAStaar Surgical | n/m |
| BVSBioventus | 11.7× |
| IARTIntegra Lifesciences | 12.3× |
| IRMDIradimed | 38.9× |
| LMATLemaitre Vascular | 25.2× |
| INSPInspire Medical Systems | 16.6× |
| UFPTUFP Technologies | n/m |
| MOVMovado | 10.0× |
| WRBYWarby Parker | 136× |
| Peer median | 20.9× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Cadre
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.